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Abstract
BACKGROUND: The aim of the study was to assess the ef-
fectiveness of peptide receptor radionuclide therapy (PRRT) 
in patients with non-functioning neuroendocrine pancreatic 
tumours (NFPNTs) and to compare survival rates in patients 
with NFPNTs and in patients with other neuroendocrine tumours 
(NETs) treated using radiolabelled somatostatin analogue in 
our Department. We would like to analyze factors potentially 
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determining the effectiveness of the therapy and also to assess 
the myelo- and nephrotoxicity. 
MATERIAL AND METHODS: Fourteen patients with dissemi-
nated disease and/or inoperable NFPNT were qualified to PRRT 
based on positive SRS (somatostatin receptor scintigraphy). 
There were 5 men and 9 women, with Karnofsky’s index > 70%. 
RESULTS: In the whole group of patients, partial response was 
observed in 21.4%, stabilization of the disease in 42.9%, and 
progression of the disease in 35.7% of patients. Mean observa-
tion time was 19 ± 13 months, mean time to progression was 
12 ± 9 months, and mean time to death was 16 ± 9 months. Six 
patients died — four of them due to progression of the disease, 
two due to myocardial infarction. After PRRT we did not observe 
clinically significant haemotoxicity and/or nephrotoxicity. 
CONCLUSIONS: 1. Peptide receptor radionuclide therapy may 
be a safe and effective treatment option in patients with NFPNTs, 
leading to stabilization or regression of the disease in the major-
ity of patients. 2. There is no statistically significant difference in 
survival rate between patients with NFPNTs and NETs of other 
localization treated with PRRT.
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Introduction
Non-functioning neuroendocrine pancreatic tumours (NFPNTs) 
are clinically silent; however, the presence of various hor-
mones such as insulin, glucagon, pancreatic polypeptide, so-
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matostatin, neurotensin, or calcitonin may be demonstrated by 
immunohistochemistry [1]. The incidence of NFPNTs has been 
reported to be 15–53% in a clinical series of pancreatic endocrine 
tumours. More than 50% of NFPNTs are malignant — this is con-
nected with their local invasion, regional lymph node metastases, 
and distant metastases especially to the liver [2]. Predominant 
symptoms are abdominal pain, weight loss, jaundice, and pan-
creatitis [3]. NFPNTs are usually localized in the posterior part of 
the pancreatic head [1, 4]. A tumour size of about 20 to 40 mm 
in diameter is a preoperative clinical risk factor for an increasing 
rate of metastases [1]. Somatostatin receptor scintigraphy (SRS) 
enables localization of pancreatic NET (neuroendocrine tumours) 
and its small, distant metastases. In some cases SRS may differ-
entiate between exocrine and endocrine pancreatic tumours [1]. 
Pancreatic adenocarcinomas are rarely diagnosed with the use 
of SRS, whereas about 65% of PNT (pancreatic neuroendocrine 
tumours) can be localized with SRS [5].
The first line treatment is surgery. Candidates for surgery are 
patients with incidental NFPNTs that are symptomatic and asymp-
tomatic patients with presumably benign tumours > 10 mm in 
diameter [1]. Whether a pancreatoduodenectomy, central pancrea-
tectomy, or distal pancreatectomy is required depends on the site 
of the tumour [3]. For asymptomatic patients with well-differentiated 
metastatic disease and therefore better prognosis, a conservative 
approach might be suggested — waiting for the progression of the 
disease or occurrence of the symptoms before initiating therapy 
such as systemic chemotherapy, hormonal therapy, radiofrequency 
ablation, selective transcutaneous arterial chemoembolization 
(TACE), or transplantation [3]. Resection of the liver metastases and 
primary tumour from patients with liver metastases seems rational 
only if complete tumour removal is possible [1]. Chemotherapy 
using a combination of streptozotocin plus 5-fluorouracil (5-FU) or 
doxorubicin has been the gold standard for treatment of different 
types of endocrine pancreatic tumours. The objective responses so 
far were assessed for 60% among treated patients, but recent 
studies using MRI/CT evaluation have reduced the objective 
responses to 16–30% [6]. Therefore, the therapeutic option for 
this group of patients has still not been found. New strategies with 
tyrosine kinase inhibitors and anti-angiogenic treatment have been 
tested [7, 8]. Peptide receptor radionuclide therapy provides the 
option to treat patients with inoperable non-functioning pancreatic 
endocrine tumours with sufficient uptake in SRS [9]. The side ef-
fects of this therapy are absolutely lower than chemotherapy and 
the median time to progression can be similar [7].
The aim of the study was to assess the effectiveness of PRRT 
(peptide receptor radionuclide therapy) in patients with non-func-
tioning neuroendocrine pancreatic tumours and to compare survival 
rates in patients with NFPNT and in patients with other NETs treated 
using radiolabelled somatostatin analogue (90Y-DOTA-TATE and 
90Y/177Lu-DOTA-TATE) in our Department. Moreover, we would like 
to analyze factors potentially determining the effectiveness of the 
therapy and also to assess the myelo- and nephrotoxicity.
Material and methods
Nineteen patients with metastatic non-functioning pancreatic 
tumours were diagnosed in the Department of Endocrinology 
UJCM or referred to our Department from other centres. 
Fourteen patients with disseminated disease and/or inoper-
able [9] NFPNT were qualified to PRRT with 90Y-DOTA-TATE and 
90Y/177Lu-DOTA-TATE based on positive SRS. There were 5 men 
and 9 women, with mean age 56.1 ± 12.8 years and Karnofsky's in-
dex > 70%. In one patient with an inoperable pancreatic tumour, no 
distal metastases were found despite a high Ki index (Ki = 20%). 
The median size of the primary tumour was 57 mm, SD 57 mm, 
min 21 mm, and max 230 mm. Thirteen patients (93%) had Ki-67 
less than 15% (WHO type 2). Each patient received 7.4 GBq/m2 of 
PRRT divided into 4–5 infusions (most often 3.7 GBq per cycle), 
every 6 to 9 weeks. For nephroprotection amino acids formula 
Vamin 18, before and after each infusion of PRRT, was adminis-
tered. In 5 patients chemotherapy (Zanosar and 5-FU) was used 
before the PRRT cycle; the mean time to start the PRRT after 
chemotherapy was 6 months. After PRRT, long-term acting so-
matostatin analogues were used in five cases. The patients’ data 
are presented in Table 1.
Among the five patients with a high proliferation index 
(Ki ≥ 20%, WHO type 3) four had a negative SRS result. The 
size of the tumours was 30 to 70 mm in diameter. One of those 
patients with a positive SRS result received one infusion of PRRT 
but was then qualified to chemotherapy. The four others received 
chemotherapy as the first line treatment.
Twenty-eight patients with disseminated NETs assessed as NET 
G2 according to WHO criteria (18 females, 10 males, aged 31–78, 
mean: 59.7 ± 11.9 years) with histopathologically confirmed NET 
and positive 99mTc-[EDDA/HYNIC]-TOC SRS were treated with PRRT 
due to progression of the disease and compared to a group of 
patients with NFPNT. There were fourteen patients with foregut tu-
mours (six with functioning pancreatic tumours), eleven with midgut 
tumours, two with hindgut tumours, and three with unknown primary 
focus (PFU). In all of the patients a similar protocol of treatment 
was used. The patients received 7.4 GBq/m2 of PRRT divided into 
4–5 infusions (most often 3.7 GBq per cycle), every 6 to 9 weeks.
SRS with the use of 99mTc-[EDDA/HYNIC]-TOC was performed 
in order to assess somatostatin receptor expression at the Nuclear 
Medicine Unit of Endocrinology Department in the University Hos-
pital in Cracow. CT examinations were performed in the 1st CT 
Unit of Radiology Department using a spiral multirow CT scanner 
— Siemens Somatom Sensation 16. The protocols of SRS and CT 
examinations have been presented earlier in detail [10]. After injec-
tion of the tracer (740 MBq), all patients underwent whole-body 
scans after 1, 4, and 24 hours and SPECT of the abdomen and/or 
thorax with use of a dual-head, large-field-of-view gamma camera 
(Siemens) with parallel, low-energy, high-resolution (LEHR) collima-
tors. Standard protocol of CT for the abdomen and pelvis and/or 
chest was performed (detector configuration 16 × 0.75 mm, slice 
thickness and reconstruction increment 2 mm, reconstruction kernel 
B31f or B41f, before and multiphase after IV non-ionic contrast media 
administration in dose 1 ml/kg, flow 2.5 ml/s, delay of arterial phase 
30 seconds and venous phase 60 seconds after the start of contrast 
administration). The semiquantitative analysis showed the uptake in 
the tumour type 2, 3, and 4 according to a four-point scale, where 
1 is uptake smaller than in the liver, 2 is uptake the same as in the 
liver, 3 is uptake bigger than in the liver, and 4 is uptake bigger than 
in the kidney and spleen. For assessment of the effectiveness of 
PRRT leading to disease regression, the SRS scans were qualitatively 
analyzed before and after therapy. For quantitative analysis, the 1–3 
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biggest changes were chosen. In CT scans measurable lesions were 
analyzed according to RECIST criteria before and after the treat-
ment. Based on SRS and CT scan fusion, the target to non-target 
ratios before and after therapy for the same lesions were assessed 
using volumetric analysis with isoconture 20%.
To assess nephro- and myelotoxicity each patient had pa-
rameters assayed such as creatinine, platelets, leukocytes, and 
haemoglobin before and every month after treatment. Myelotoxic-
ity was assessed according to WHO classification. The level of 
chromogranin A (CgA) was measured prior to and after PRRT.
Statistical methods
The correlation between T/nT ratio difference in SRS before and 
after treatment and lesion cross-section difference in CT before and 
after treatment was assessed using Pearson’s correlation coef-
ficient. The statistical connection between the size of the primary 
tumour and response to PRRT, and also between the amount of 
therapeutic activity and response to PRRT, were assessed using 
Kruskal-Wallis test. The connection between surgical intervention 
prior to PRRT and response to the therapy was assessed (using 
U Mann-Whitney test). Kaplan-Meier curves and Cox F test were 
used for the comparison of the two groups’ survivals: the first 
group — patients treated with non-functioning pancreatic tumours 
(6 complete observations, 8 censored observations, mean time of 
observation 21.2 months ± 14.9 months, max 52.5 months, min 
5.9 months), the second group — patients treated with the PRRT 
because of diseases other than non-functioning pancreatic tu-
mours (8 complete observations, 20 censored observations, mean 
time of observation 26.6 months ± 15.3 months, max 77.3 months, 
min 6.1 months). The second group consisted of 28 patients.
A 95% confidence level was assumed in all statistical analysis.
Results 
Thirteen out of fourteen patients received 90Y-DOTA-TATE in 
4–5 infusions; the minimum activity was 11.1 GBq, maximum 
15.54 GBq (median activity 13.32 GBq). One patient received a mix 
of 90Y/177Lu-DOTA-TATE (total activity 10.36 GBq).
In the whole group of patients, partial response was observed 
in 21.4%, stabilization of the disease in 42.9%, and progression of 
the disease in 35.7%. Mean observation time was 19 ± 13 months, 
mean time to progression was 12 ± 9 months, and mean time to 
death was 16 ± 9 months. Six patients died – four of them due to 
progression of the disease and two due to myocardial infarction. 
Two patients received a repeated cycle of PRRT, the first — one 
application of 3.7 GBq 18 months after the end of the first PRRT 
cycle, and the second — one application of 2.96 GBq 8 months af-
ter the end of the first PRRT cycle. One of them died one month 
after the second PRRT cycle. 
Semiquantitative analysis of the tracer uptake in SRS showed 
uptake types 3 and 4 in metastases of the tumours in 6 and 7 of 
the cases, respectively, and 3 and 4 in primary tumours in 3 and 
5 of the cases, respectively. Two patients with metastases of PNT 
had somatostatin receptor expression in metastases only (not in 
primary tumour). In the group with uptake 4 in liver metastases after 
the treatment, five patients had uptake type 3 and two uptake type 
2. In the whole group of patients with uptake 4 in the metastases, 
stabilization of the disease was observed in three cases, regres-
sion in two, and progression in two patients after the PRRT. In the 
whole group with uptake type 3 after the PRRT, stabilization of 
the disease was observed in two cases, regression in one, and 
progression in three patients. 
In the group of nine patients with inoperable PNT, regression 
of the primary tumour after PRRT was observed in one of them. 
Table 1. Patients with non-functioning neuroendocrine pancreatic tumours
Initials Age Sex Size of tumor 
[mm]
Localization Meta Surgery Y-90 DOTA-TATE 
therapy
PRRT Y-90 
[GBq]
Chemotherapy Response 
to the PRRT
MK 33 F 58 Tail Lymph nodes, 
cns
Explorative 
laparotomy
Y90/Lu177 — 
11.2008– 09.2009
10.36 Y PD
TO 73 F 21 Head Liver N 08.2006–11.2006 11.10 N PR
WK 54 F 49 Tail Liver Explorative 
laparotomy
06.2008–01.2009 12.58 N SD
DM 71 F 26 Tail Liver Explorative 
laparotomy
07.2007–12.2007; 
and 06.2009
11.84 + 3.70 Y PD
RN 34 F 230 Tail Liver N 09.2009–03.2010 13.32 Y PD
JO 77 F 150 Tail Liver N 11.2005–03.2006 13.32 N PR
AP 56 M 88 Head and 
stem
Liver Explorative 
laparotomy
09.2009–02.2010 13.32 N SD
JP 52 F 57 Stem and tail Liver Y 2006 14.80 Y SD
TR 61 M 122 Stem Liver N 05.2009–09.2009 14.80 N PD
HT 60 F 105 Head and 
stem
No N 02.2007–09.2007 12.58 N SD
ZW 60 M 57 Tail and stem Liver Y 07.2007–12.2007 11.84 N PD
AŻ 54 F 56 Tail and stem Liver Y 08.2007–01.2008 13.32 Y PR
SD — stable disease; PD — progressive disease; PR — partial response; CNS — central nervous system; N — no; Y — yes
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Additionally, in three patients regression of the liver lesions was ob-
served. But in one of them, 18 months later, progression of the 
disease was observed. We observed stabilization of the disease 
in three of the patients.
There was no correlation between the grade of the uptake in 
SRS and response to the therapy. The patients with uptake types 3 
and 4 in SRS had either regression or progression of the disease. 
In the case of disease regression, we observed a decline in the 
target/non-target ratio and a decline in the dimensions of the tu-
mour in a CT scan. There was, however, no statistically significant 
correlation between T/nT ratio difference in SRS before and after 
treatment and lesions cross-section difference in CT before and 
after treatment (Figure 1 and Figure 2).
There was no statistically significant relationship between 
the amount of therapeutic activity and response to the therapy 
(p = 0.60). There was also no statistically significant relationship 
between surgical intervention prior to PRRT and response to the 
therapy.  The same result was observed for the size of the primary 
tumour and response to PRRT (p = 0.95 and p = 0.45, respectively).
The comparison of the survival rates between the group 
of patients with NFPNT and patients with neuroendocrine 
tumours at other localizations treated in our Department with 
PRRT, particularly midgut tumours, did not show any statisti-
cally significant difference (Figure 3). Median survival time (the 
survival time at which the cumulative survival function is equal 
to 0.5) for the first group was 25.7 months and for the second 
group was 46.7 months.
After PRRT we did not observe clinically significant haemo-
toxicity and/or nephrotoxicity. According to WHO classification, 
transient myelotoxicity grade 2 in leucocyte level was observed 
in three patients. In eight cases, transient toxicity grade 2, and 
in one patient grade 3 in haemoglobin level was observed. That 
patient required a blood transfusion. We have not observed toxicity 
types 2, 3, or 4 in platelet levels so far. 
In three patients, the creatinine level was higher than normal 
20 months after commencing therapy, but without clinical symp-
toms of renal insufficiency (Figure 4).
We observed a decrease in the values of the morphological 
parameters compared to initial values in consecutive months after 
commencing therapy in the whole group of patients, but the medi-
an values for each parameter were within normal ranges (Figure 5). 
The levels of liver parameters did not change after therapy. 
There was no statistically significant correlation between the 
chromogranin A level and the response to the therapy.
Discussion
Patients with non-functioning pancreatic tumours (NFPNTs) do 
not usually present any specific symptoms, and therefore they are 
usually discovered in the advanced stage with distant, usually liver, 
metastases, which are often the first symptom of the disease. The 
best treatment option in patients with pancreatic neuroendocrine 
tumours is surgery [1, 3, 9–11]. Surgical resection is also beneficial 
for patients with advanced, disseminated malignant pancreatic 
Figure 3. Comparison of survival of patients with non-functioning 
neuroendocrine pancreatic tumours (NFPNTs) and patients with 
neuroendocrine tumours (NETs) of different localization.
Figure 1. Lesions in the liver prior to and after peptide receptor 
radionuclide therapy (PRRT) — uptake in somatostatin receptor 
scintigraphy (SRS) and size in computed tomography (CT) studies. 
Figure 2. Primary pancreatic tumours prior to and after peptide 
receptor radionuclide therapy (PRRT) — uptake in somatostatin 
receptor scintigraphy (SRS) and size in computed tomography (CT) 
studies. 
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tumours [11, 13]. However, surgery is not possible in all patients 
[1, 3]. The effectiveness of chemotherapy appears to be lower than 
previously estimated [6]. Treatment with radiolabelled somatostatin 
analogues might be another therapeutic approach in the case of 
patients with NFPNTs with sufficient uptake in SRS. 
In our group of 14 patients, in five cases surgery was not 
performed and in four cases an explorative laparotomy revealed 
inoperable pancreatic tumours. Only one patient did not have 
distant metastases at the time of diagnosis. With the exception of 
one case — a patient with inoperable primary tumour without dis-
tant metastases and Ki-67 20%, almost all our patients had Ki-67 
less than 15%. All patients had positive results of SRS studies, and 
were therefore qualified to peptide receptor radionuclide therapy. 
Five of them underwent previous chemotherapy. The response to 
the therapy was assessed with standard criteria for solid tumour, 
which took into consideration only the tumour size. We were trying 
to find out whether the changes in SRS after PRRT might be useful in 
assessment of the response to the therapy. There was no correlation 
between the grade of the uptake in SRS and response to the therapy. 
Therefore, the uptake ratio could not be considered as a prognostic 
factor for the therapy response. In the case of disease regression 
a decline in the target/non-target ratio corresponded with the de-
cline in the dimensions of the tumour in a CT scan. According to 
RECIST criteria, we observed disease stabilization in nearly 50% 
of patients and partial response to the therapy was seen in 21.4% 
of cases. But we did not find any predictors of the effectiveness of 
the PRRT because there was no correlation between the uptake 
grade in SRS and response to therapy as mentioned above, and 
also between target non-target ratio difference in SRS before and 
after treatment and lesion cross-section difference in CT before and 
after treatment. There was also no correlation between tumour size 
and response to the PRRT. Surgical intervention prior to radioisotope 
therapy also did not correlate with the results of the previous one. 
But a very important factor in the safety of the therapy is that there 
was no clinically significant myelotoxicity and/or nephrotoxicity 
observed after PRRT in our group of patients.
In one of our patients we observed regression in the primary 
inoperable pancreatic tumour size after PRRT [10]. The patient 
Figure 5. Morphological parameter levels after peptide receptor 
radionuclide therapy (PRRT). HgB — hemoglobin; WBC — white 
blood cells; PLT — platelets.
Figure 4. Creatinine levels after peptide receptor radionuclide therapy 
(PRRT). 
was referred to the Department of Surgery, but the surgical 
resection of the tumour was still not possible due to infiltration 
of the large vessels. The regression of the tumour size, as also 
suggested by other authors, is an indication that PRRT might 
also be considered as neoadjuvant therapy in the case of pa-
tients with pancreatic tumours [9, 10, 12]. Moreover, Stoeltzing 
et al. presented a case showing that PRRT might be used also 
to decrease the size of liver metastases of pancreatic neuroen-
docrine tumours and therefore further improve surgical therapy 
of hepatic lesions [13].  
We also compared the survival rate in the group of patients with 
pancreatic neuroendocrine tumours and patients with NETs of 
other localization treated in our Department with radiolabelled 
somatostatin analogues. We did not find any statistically significant 
difference in survival rates between these two groups of patients. 
We believe this is an important finding because, as presented by 
Panzuto et al., a pancreatic site of the primary tumour represented 
as an independent variable predictive of an unfavourable out-
come [14]. Despite the nonsignificant difference between survival 
curves in these two groups, a difference between median survival 
times could be observed. The explanation of this fact may be the 
generally known worse response of NFPNTs to the PRRT. How-
ever, we assess responses to PRRT in our group of patients with 
NFPNTs as very good.
The observation that the survival rate for patients with pancre-
atic NETs treated with PRRT was similar to that of patients with 
other NET localizations, along with the effects presented above 
and the safety of the therapy with radiolabelled somatostatin 
analogues, confirms the usefulness and effectiveness of PRRT 
as a therapeutic option in patients with inoperable and/or dis-
seminated non-functioning pancreatic tumours.
Conclusions
1.  Peptide receptor radionuclide therapy may be a safe and 
effective treatment option in patients with non-functioning 
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pancreatic neuroendocrine tumours leading to stabilization or 
regression of the disease in the majority of patients.
2.  There is no statistically significant difference in survival 
rates between patients with pancreatic neuroendocrine tu-
mours and NETs of other localizations treated with PRRT. 
Dates of any congresses at which the paper has already been 
presented: XII Congress of the Polish Association of Nuclear 
Medicine, Wroclaw 2010; 10th Annual Congress of the European 
Association of Nuclear Medicine, Vien 2010 (mentioned during 
the highlight lecture); 14th International Congress of Endocrino-
logy, Kyoto 2010.
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